EP
OTLK icon

Essential Partners’s Outlook Therapeutics OTLK Stock Holding History

Essential Partners’s Portfolio OTLK Stock Details OTLK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-43
Closed -$69 – 2756
2025
Q2 		$69 Buy
+43
New +$69 ﹤0.01% 2115

Other funds holding OTLK

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $171B AUM 85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Essential Partners's OTLK Position: Q3 2025 in Review

Essential Partners sold out of Outlook Therapeutics (OTLK) in Q3 2025, closing a stake of 43 shares — an estimated $69 sold.

Essential Partners first reported a position in OTLK in Q2 2025 and held it in 1 quarter. The position peaked at $69 in Q2 2025. 54 funds tracked by Wall St. Rank hold OTLK as of Q3 2025.

  • Essential Partners reported no remaining Outlook Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Essential Partners sold 43 Outlook Therapeutics shares in Q3 2025, an estimated $69.
  • Essential Partners first reported a position in Outlook Therapeutics in Q2 2025 and held it in 1 quarter.
  • Essential Partners's Outlook Therapeutics position peaked at $69 in Q2 2025.
  • 54 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q3 2025.

Based on Essential Partners's 13F filing for Q3 2025, filed 21 May 2026.